Solventum to Acquire Acera Surgical for $725M Plus $125M in Milestones, Expanding into Synthetic Tissue Matrices

St. Paul, MN, November 20, 2025 (PRNewswire) -- Solventum (NYSE: SOLV) will acquire Acera Surgical, a private bioscience company specializing in fully engineered materials for regenerative wound care, for $725 million in cash plus up to $125 million in milestone-based payments. Acera, founded in 2013, markets Restrata® products in the U.S., used to treat complex, hard-to-heal wounds in acute care settings.

Read full article here.